<DOC>
	<DOCNO>NCT00725205</DOCNO>
	<brief_summary>Participants receive PegIntron injection pen ( Peginterferon alfa-2b ) Rebetol ( Ribavirin ) combination therapy usual medical treatment . The current study aim evaluate whether previously introduce , widely accept implemented educational program , represent additional effort everyday practice increase patient compliance , succeed achieve adherence rate treat participant similar extent demonstrate clinical trial .</brief_summary>
	<brief_title>Patient Compliance During PegIntron Rebetol Combination Therapy Chronic Hepatitis C ( Study P04690 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Before inclusion , participant must inform must give consent use his/her anonymized health data relate his/her treatment Peginterferon alfa2b ( injection pen ) Ribavirin . According Peginterferon alfa2b/Ribavirin label .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>